Using the CRISPR-Cas9 technology, we previously established 293T and HepG2 cells with LMAN1 or MCFD2 KO and fo

/Using the CRISPR-Cas9 technology, we previously established 293T and HepG2 cells with LMAN1 or MCFD2 KO and found reduced rates of ER-Golgi transport of AAT in these cells... However, FV secretion in HCT116-/- cells only decreased mildly, to ~80% of the HCT116+/- level... FVIII activity and antigen levels decreased in all 293T and HepG2 KO cell lines... to less than 10% level of WT cells... reduction of FVIII in conditioned media of HCT116-/- cells was less profound, to only ~50% level of HCT116+/- cells.